Brain tumor animal models: Importance and progress

Current Opinion in Oncology

Volumn 13, Issue 3, 2001, Pages 143-147

  Holland, Eric C ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; BRAIN CANCER; BRAIN TUMOR; CHOROID PLEXUS; GENE EXPRESSION REGULATION; GENE TECHNOLOGY; GLIOMA; HISTOPATHOLOGY; MEDULLOBLASTOMA; MOUSE; NONHUMAN; PAPILLOMA; PRIORITY JOURNAL; REVIEW;

ANIMALS; BRAIN NEOPLASMS; DISEASE MODELS, ANIMAL; FORECASTING; GLIOMA; HUMANS; MEDULLOBLASTOMA; MICE; MICE, TRANSGENIC; PAPILLOMA, CHOROID PLEXUS;

EID: 0035041020     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200105000-00002     Document Type: Review

References (38)

1. 1 Russel DS, Rubenstein LJ: Pathology of tumors of the nervous system, Baltimore: Williams and Wilkins; 1989.
2. 2 Kleihues P, Cavenee W (eds): Pathology and Genetics of Tumors of the Nervous System. Lyon: IARC; 2000. The current WHO classification of CNS tumors associated with an excellent review of the underlying biology.
3. 3 Holland EC: Glioblastoma multiforme: the terminator. Proc Natl Acad Sci U S A 2000, 97:6242-6244. A discussion of the difficulties applying mouse model data to success in treating humans with brain tumors.
4. 4 Aguzzi A, Brandner S, Isenmann S, et al.: Transgenic and gene disrupution techniques in the study of neurocarcinogenesis. Glia 1995, 15:348-364.
5. 5 Macleod KF, Jacks T: Insights into cancer from transgenic mouse models. J Pathol 1999, 187:43-60.
6. 6 Fisher GH, Orsulic S, Holland EC, et al.: Development of a flexible and specific gene delivery system for production of murine tumor models. Oncogene 1999, 18:5253-6260.
7. 7 Holland EC Gliomagenesis: genetic alterations and mouse models. Nat Rev Genet 2001, 2:1-10. An extended review of the pathways leading to gliomagenesis and mouse models that recapitulate the genetics and histologic characteristics of the disease.
8. 8 Nobel M, Mayer-Proschel M: Growth factors, glia and gliomas. J Neurooncol 1997, 35:193-209.
9. 9 Ford HL, Pardee AB: Cancer and the cell cycle. J Cell Biochem 1999, suppl 32-33:166-172.
10. 10 Ichimura K, Schmidt EE, Goike HM, et al.: Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. Oncogene 1996, 13:1065-1072.
11. 11 Jen J, Harper JW, Bigner SH, et al.: Deletion of p16 and p15 genes in brain tumors. Cancer Res 1994, 15:6353-6358.
12. 12 Raffel C, Ueki K, Harsh GR 4th, et al.: The multiple tumor suppressor 1/cyclin-dependent kinase inhibitor 2 gene in human central nervous system primitive neuroectodermal tumor. Neurosurgery 1995, 36:971-974.
13. 13 Adesina AM, Nalbantoglu J, Cavenee WK: p53 gene mutation and mdm2 gene amplification are uncommon in medulloblastoma. Cancer Res 1994, 54:5649-5651.
14. 14 Biegel JA, Burk CD, Barr FG, et al.: Evidence for a 17p tumor related locus distinct from p53 in pediatric primitive neuroectodermal tumors. Cancer Res 1992, 52:3391-3395.
15. 15 Donehower LA, Harvey M, Slagle BL, et al.: Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature 1992, 356:215-221.
16. 16 Jacks T, Fazeli A, Schmitt EM, et al.: Effects of an Rb mutation in the mouse. Nature 1992, 359:295-300.
17. 17 Kamijo T, Bodner S, van de Kamp E, et al.: Tumor spectrum in ARF-deficient mice. Cancer Res 1999, 59:2217-2222. Demonstration that specific loss of p19ARF can contribute to oligodendroglioma formation.
18. 18 McKinnon RD, Matsui T, Dubois-Dalcq M, et al.: FGF modulates the PDGF-driven pathway of oligodendrocyte development. Neuron 1990, 5:603-614.
19. 19 Mayer M, Bogler O, Nobel M: The inhibition of oligodendrocytic differentiation of O2A progenitors caused by basic fibroblast growth factor is overridden by astrocytes. Glia 1993, 8:12-19.
20. 20 Bogler O, Wren D, Barnett S, et al.: Cooperation between two growth factors promotes extended self-renewal and inhibits differentiation of oligodendrocyte-type 2 astrocyte (O2A) progenitor cells. Proc Natl Acad Sci U S A 1990, 87:6368-6372.
21. 21 Rajan P, McKay RD: Multiple routes to astrocytic differentiation in the CNS. J Neurosci 1998, 18:3620-3629.
22. 22 Wessenberger J, Steinbach JP, Malin G, et al.: Development and malignant progression of astrocytomas in GFAP-v-src transgenic mice. Oncogene 1997, 14:2005-2013.
23. 23 Holland EC, Li Y, Celestino J, et al.: Astrocytes can give rise to oligodendrocytomas and astrocytomas after transfer of middle T antigen in mice. Am J Pathol 2000, 157:1031-1037. Demonstration that activation of signal transduction pathways can cause differentiated astrocytes to give rise to oligodendrogliomas and astrocytomas.
24. 24 Uhrbom L, Hesselager G, Nister M, et al.: Induction of brain tumors in mice using a recombinant platelet-derived growth factor B-chain retrovirus. Cancer Res 1998, 58:5275-5279.
25. 25 Holland EC, Celestino J, Dai C, et al.: Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 2000, 12:55-57. Demonstration that the combination of Ras and Akt signaling leads to glioblastoma formation.
26. 26 Reilly KM, Loisel DA, Bronson RT, et al.: Nf1; Trp53 mutant mice develop glioblastoma with evidence of strain-specific effects. Nat Genet 2000, 26:109-113. Demonstration that loss of the NF1 gene product that regulates Ras signaling can cooperate with p53 loss to form high-grade gliomas in mice.
27. 27 Wechsler-Reya RJ, Scott MP: Control of neuronal precursor proliferation in the cerebellum by sonic hedgehog. Neuron 1999, 22:103-114.
28. 28 Dahmane N, Ruiz-i-Altaba A: Sonic hedgehog regulates the growth and patterning of the cerebellum. Development 1999, 126:3089-3100.
29. 29 Jessell TM, Sanes JR: Development. The decade of the developing brain. Curr Opin Neurobiol 2000, 10:599-611. An excellent review of the molecular mechanisms regulating the development of the central nervous system.
30. 30 Hahn H, Wicking C, Zaphiropoulous PG, et al.: Mutations of the human homolog of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 1996, 85:841-51.
31. 31 Gorlin RJ: Nevoid basal-cell carcinoma syndrome. Medicine 1987, 66:98-113.
32. 32 Raffel C, Jenkins RB, Frederick L, et al.: Sporadic medulloblastomas contain PTCH mutations. Cancer Res 1997, 57:842-845.
33. 33 Goodrich LV, Milenkovic L, Higgins KM, et al.: Altered neural cell fates and medulloblastoma in mouse patched mutants. Science 1997, 277:1109-1113.
34. 34 Zurawel RH, Allen C, Wechsler-Reya R, et al.: Evidence that haploinsufficiency of Ptch leads to medulloblastoma in mice. Genes Chromosomes Cancer 2000, 28:77-81.
35. 35 Wetmore C, Eberhart DE, Curran T: The normal patched allele is expressed in medulloblastomas from mice with heterozygous germ-line mutation of patched. Cancer Res 2000, 60:2239-2246.
36. 36 Brinster RL, Chen HY, Messing A, et al.: Transgenic mice harboring SV40 T-antigen genes develop characteristic brain tumors. Cell 1984, 37:367-379.
37. 37 Bowman T, Symonds H, Gu L, et al.: Tissue-specific inactivation of p53 tumor suppression in the mouse. Genes Dev 1996, 10:826-835.
38. 38 Marino S, Vooijs M, van Der Gulden H, et al.: Induction of medulloblastomas in p53-null mutant mice by somatic inactivation of Rb in the external granular layer cells of the cerebellum. Genes Dev 2000, 14:994-1004. Demonstration that loss of p53 and Rb in certain cell types during development leads to the formation of medulloblastomas.